BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Narzo AF, Brodmerkel C, Telesco SE, Argmann C, Peters LA, Li K, Kidd B, Dudley J, Cho J, Schadt EE, Kasarskis A, Dobrin R, Hao K. High-Throughput Identification of the Plasma Proteomic Signature of Inflammatory Bowel Disease. J Crohns Colitis 2019;13:462-71. [PMID: 30445421 DOI: 10.1093/ecco-jcc/jjy190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Lippai R, Veres-Székely A, Sziksz E, Iwakura Y, Pap D, Rokonay R, Szebeni B, Lotz G, Béres NJ, Cseh Á, Szabó AJ, Vannay Á. Immunomodulatory role of Parkinson's disease 7 in inflammatory bowel disease. Sci Rep 2021;11:14582. [PMID: 34272410 DOI: 10.1038/s41598-021-93671-1] [Reference Citation Analysis]
2 Ozen A, Kasap N, Vujkovic-Cvijin I, Apps R, Cheung F, Karakoc-Aydiner E, Akkelle B, Sari S, Tutar E, Ozcay F, Uygun DK, Islek A, Akgun G, Selcuk M, Sezer OB, Zhang Y, Kutluk G, Topal E, Sayar E, Celikel C, Houwen RHJ, Bingol A, Ogulur I, Eltan SB, Snow AL, Lake C, Fantoni G, Alba C, Sellers B, Chauvin SD, Dalgard CL, Harari O, Ni YG, Wang MD, Devalaraja-Narashimha K, Subramanian P, Ergelen R, Artan R, Guner SN, Dalgic B, Tsang J, Belkaid Y, Ertem D, Baris S, Lenardo MJ. Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease. Nat Immunol 2021;22:128-39. [PMID: 33398182 DOI: 10.1038/s41590-020-00830-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kumar M, Garand M, Al Khodor S. Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine. J Transl Med 2019;17:419. [PMID: 31836022 DOI: 10.1186/s12967-019-02174-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
4 Daniluk U, Daniluk J, Guzinska‐ustymowicz K, Pryczynicz A, Lebensztejn D. Usefulness of metalloproteinase‐9 and tissue inhibitor of metalloproteinase‐1 in clinical characterisation of children with newly diagnosed Crohn's disease. J Paediatr Child Health 2020;56:1233-41. [DOI: 10.1111/jpc.14908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xu M, Kong Y, Chen N, Peng W, Zi R, Jiang M, Zhu J, Wang Y, Yue J, Lv J, Zeng Y, Chin YE. Identification of Immune-Related Gene Signature and Prediction of CeRNA Network in Active Ulcerative Colitis. Front Immunol 2022;13:855645. [PMID: 35392084 DOI: 10.3389/fimmu.2022.855645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pap D, Veres-Székely A, Szebeni B, Vannay Á. PARK7/DJ-1 as a Therapeutic Target in Gut-Brain Axis Diseases. Int J Mol Sci 2022;23:6626. [PMID: 35743072 DOI: 10.3390/ijms23126626] [Reference Citation Analysis]